Navigation Links
Media Advisory: ACC Updated Schedule

Schering-Plough Announces Presentation Of Phase II Trial Results For Novel Oral Thrombin Receptor Antagonist At The 2007 Annual Meeting Of The American College Of Cardiology/i2 Summit

KENILWORTH, N.J., March 16, 2007 /PRNewswire-FirstCall/ -- Schering-Plough Corporation announced today that results of the Phase II trial of its novel oral thrombin receptor antagonist (TRA) SCH 530348 will be presented at the 2007 annual Scientific Sessions of the of Cardiology (ACC.07)/Innovation in Intervention (i2) Summit, March 24-27 in New Orleans. The Phase II trial, referred to as the Thrombin Receptor Antagonist in Percutaneous Coronary Intervention (TRA-PCI) trial, has been accepted as a late-breaker presentation.

The trial was designed to evaluate the safety and tolerability of Schering-Plough's TRA coadminstered with standard of care antithrombotic therapy (including aspirin and clopidogrel) in patients undergoing percutaneous coronary intervention (PCI). A secondary objective was to assess whether patients treated with the compound had fewer cardiovascular events such as heart attack, need for urgent coronary revascularization, or death at 60 days compared with patients treated with the standard of care.

TRA Late-Breaker Trial Data Presentation:

Results of a Multinational Randomized, Double-Blind, Placebo-Controlled Study of a Novel Thrombin Receptor Antagonist SCH 530348 in Percutaneous Coronary Intervention, David J. Moliterno, MD, Chief of Cardiovascular Medicine, University of Kentucky School of Medicine, for the TRA-PCI Investigators, Saturday, March 24, 11:45AM - 11:55AM, Ernest N. Morial Convention Center, La Nouvelle Orleans C.

Dr. Moliterno will participate in the ACC press conference immediately following (12:00PM - 1:00PM) in Rooms 215-216, just above Hall A.

About Schering-Plough Corporation

Schering-Plough is a global science-based health care company with leading
'"/>




Page: 1 2

Related medicine technology :

1. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
2. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
3. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
4. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
5. Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
6. Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II trial of Cloretazine (VNP40101M) in Patients with Relapsed or Refractory Small Cell Lung Cancer
7. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
8. Avanir Pharmaceuticals Presents IEED Prevalence and Updated Zenvia Long-Term Safety Data at AAN Annual Meeting
9. Boston Scientific Announces Schedule for EuroPcr 2007
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Media Advisory ACC Updated Schedule
(Date:11/21/2014)...   Wellcentive , the industry leader in ... announced today being named one of the four ... .  Sponsored by Intel, the world leader in ... recognizes companies developing leading-edge technology and unique approaches ... Wellcentive,s Mason Beard , senior ...
(Date:11/18/2014)... Nov. 18, 2014  NxStage ® Medical ... manufacturer of innovative dialysis products , today ... dialyzer for the in-center, hemodialysis market.  Streamline ... is designed to reduce the amount of labor ... number of touch point contamination sites.  The dialyzer ...
(Date:11/18/2014)... 18, 2014 Breast cancer will interrupt ... year who get a new diagnosis. The Commission ... for case managers to help those diagnosed with ... myriad physical, emotional and financial decisions that come ... no cost via the Commission,s online knowledge resource, ...
Breaking Medicine Technology:Wellcentive Named Finalist for 2014 Intel Innovation Award 2Wellcentive Named Finalist for 2014 Intel Innovation Award 3NxStage Launches New Streamline Express Dialyzer With Pre-attached Blood Tubing Set 2New Breast Cancer Resources: Commission For Case Manager Certification Adds Specialty Tools to Case Management Body of Knowledge Online Learning Center 2
... HeartSine ® Technologies, Inc., a world leader in ... work together with the Newtown Township Police Department (Pennsylvania) ... AED (Automated External Defibrillator) in every squad car. ... donated the HeartSine samaritan ® PAD 300P Public ...
... Electronics (AEX: PHI, NYSE: PHG ) today announced ... at four customer sites in North America, bringing clinicians uncompromised ... on display at the 97th annual meeting of the Radiological ... Mammography is the primary tool used to aid ...
Cached Medicine Technology:HeartSine® Technologies and the Newtown Township Police Join Forces 2HeartSine® Technologies and the Newtown Township Police Join Forces 3Philips MicroDose Next Generation Mammography Solution Gains Traction with First North American Customers, Enabling Excellent Image Quality at a Low Radiation Dose 2Philips MicroDose Next Generation Mammography Solution Gains Traction with First North American Customers, Enabling Excellent Image Quality at a Low Radiation Dose 3
(Date:11/22/2014)... FRIDAY, Nov. 21, 2014 (HealthDay News) -- Many young ... smoke, but a new study finds fumes from the ... been linked to an increased risk for leukemia in ... 21 in the journal Cancer Epidemiology, Biomarkers & ... hookah tobacco smoking is not a safe alternative to ...
(Date:11/22/2014)... Steven Reinberg HealthDay Reporter ... better when patients are treated in an ambulance by a ... researchers report. The sooner patients get the clot dissolver ... after a stroke, the researchers noted. For the best outcome, ... after stroke symptoms start, the researchers said. "The so-called ...
(Date:11/22/2014)... HealthDay Reporter FRIDAY, Nov. 21, ... homes may commonly deal with aggressive or inappropriate behavior from ... 10 centers in New York state found that, in the ... were involved in some type of incident with a fellow ... someone yelling or cursing at another resident. In other cases, ...
(Date:11/21/2014)... Los Angeles, CA (PRWEB) November 21, 2014 ... is now creating picture-perfect smiles for patients in preparation ... are bonded to the fronts of teeth, look completely ... flaws. In certain situations, veneers are also valued for ... for most patients and can be used on one ...
(Date:11/21/2014)... 2014 (HealthDay News) -- Seeking to make it tougher ... and Drug Administration on Thursday approved a new hydrocodone ... -- best known by the brand name Vicodin -- ... to a surge in dangerous addictions across the United ... ER (hydrocodone bitartrate) is an extended-release tablet to treat ...
Breaking Medicine News(10 mins):Health News:Hookahs Deliver Toxic Benzene in Every Puff, Study Shows 2Health News:Special Ambulance Delivers Vital Stroke Care More Quickly 2Health News:Special Ambulance Delivers Vital Stroke Care More Quickly 3Health News:Senior-to-Senior Aggression Common in U.S. Nursing Homes 2Health News:Senior-to-Senior Aggression Common in U.S. Nursing Homes 3Health News:Los Angeles Porcelain Veneers Dentist, Dr. Kevin Sands, Now Creates Picture-Perfect Smiles for Patients for the Holiday Season 2Health News:FDA Approves 'Abuse-Resistant' Narcotic Painkiller 2Health News:FDA Approves 'Abuse-Resistant' Narcotic Painkiller 3
... A study has indicated that inflammatory bowel disease in women ... two times.// , ,Diseases such as Crohn's disease and ... weight babies or premature babies. Yet, the 'silver lining' exists ... has certainly reduced the risks. ,The St. ...
... by a US research company has highlighted the overriding ... health// problem facing society and their children today. , ... adults, found that nearly 27% named 'obesity', as the ... followed next with 16% strongly advocating action, while ...
... that could be used as a bioterrorist tool eludes ... better understood, University of Iowa// researchers report in the ... ,This bacterium, Francisella tularensis, is found naturally in ... insect bites, contact with infected rabbits or ingesting contaminated ...
... Food Technology Plant Special Research Centre (CeRPTA) is a ... called as gluten sensitive enteropathy. This product was successfully ... enhanced nutritive value and increased shelf life. ... sufferers to follow a strictly gluten-free diet for their ...
... of Texas M. D. Anderson Cancer Center suggest that the ... 40 years reduced the tumor growth in the// human pancreas ... ,The Journal of the National Cancer Institute issued on Dec.20 ... is three times more effective than just the administration of ...
... resonance imaging technique developed at the University of ... of neurological problems, such as// Chiari malformations, hydrocephalus ... use through a $1.4 million National Institutes of ... project, which draws on bioengineering, radiology and neurosurgery, ...
Cached Medicine News:Health News:Clues Found On How Deadly Bacterium Gains Foothold 2Health News:Clues Found On How Deadly Bacterium Gains Foothold 3Health News:Gluten Free Bread: Boon for Celiac Disease 2Health News:Anti Allergy Drugs Reduce Tumor Growth 2Health News:Anti Allergy Drugs Reduce Tumor Growth 3Health News:New MRI Technique Measures Intracranial Pressure in Brain Disorder 2
For the quantitative in vitro determination of Lipase in human serum and plasma....
Enzymatic Clearance assay for the in vitro quantitative determination of HDL-cholesterol in human serum and plasma....
For the quantitative in vitro determination of Ammonia in plasma...
For the quantitative in vitro determination of Potassium in serum or plasma....
Medicine Products: